Lars Cato Svendsen
About Lars Cato Svendsen
Lars Cato Svendsen is a Produktspesialist at Bristol-Myers Squibb in New Jersey, with over a decade of experience in the pharmaceutical industry.
Company
Lars Cato Svendsen is currently employed at Bristol-Myers Squibb in New Jersey, United States, where he holds the position of Produktspesialist. He contributes to the organization's pharmaceutical advancements and plays a crucial role in their product management and specialization efforts.
Title
Lars Cato Svendsen holds the title of Produktspesialist. In his current role at Bristol-Myers Squibb, he utilizes his extensive experience within the pharmaceutical industry to enhance product development and management.
Previous Experience at Pfizer
From 2001 to 2010, Lars Cato Svendsen worked at Pfizer as Bm in New York, New York, United States. Over nine years, he gained significant experience and contributed to the company's pharmaceutical projects and initiatives.
Previous Experience at Janssen Pharmaceuticals
Lars Cato Svendsen's tenure at The Janssen Pharmaceutical Companies of Johnson & Johnson spans 11 years. He initially worked as Bm from 1991 to 2001 and later as Prosjektler from 1994 to 1995, both in Raritan, New Jersey. In these roles, he played a pivotal part in various project management and business initiatives.
Education and Expertise
Lars Cato Svendsen achieved his Master's degree between 1998 and 2000. He also studied at Lund University from 1998 to 1999. Additionally, he holds a background in Biology from the Norwegian School of Sport Sciences (NIH), where he studied from 1985 to 1989. His academic and professional background equips him with a robust foundation in the pharmaceutical field.
Industry Background
Lars Cato Svendsen began his career in the pharmaceutical industry in 1991 and has since amassed significant experience working in both New York and New Jersey. With over a decade of experience in New Jersey, he has honed his expertise in various roles within the pharmaceutical sector, contributing to major industry players like Pfizer, Janssen Pharmaceuticals, and now, Bristol-Myers Squibb.